This Contract Research Company Reports 31 Per Cent Q4 Revenue Growth, Declares Rs 2 Dividend, Proposes 1:1 Bonus Share Issue, and Announces Entry Into Biologics R&D Services Expansion
Over the past six months, the stock has surged 86 per cent, and it has delivered over 1,100 per cent returns in the past five years.
On Tuesday, shares of Vimta Labs Ltd were trading at Rs 1,021.30, down 0.45 per cent from the previous close. Over the past six months, the stock has surged 86 per cent, and it has delivered over 1,100 per cent returns in the past five years. However, it is currently trading 13 per cent below its 52-week high. On Monday, the company’s board released its financial results, declared a final dividend, and proposed a bonus share issue.
Vimta Labs Limited, a Contract Research and Testing Organisation, reported its financial results for the fourth quarter and the financial year ended March 31, 2025. The total income for Q4 FY25 stood at Rs 96.08 crore, marking a 31.4 per cent rise compared to Rs 73.12 crore in Q4 FY24. EBITDA was Rs 34.68 crore with a margin of 36.1 per cent, and PAT came in at Rs 18.32 crore, resulting in a PAT margin of 19.1 per cent. For the full year FY25, total income reached Rs 348.22 crore, a 19.1 per cent increase from Rs 292.31 crore in FY24. EBITDA stood at Rs 126.19 crore, while PAT was Rs 66.76 crore. The board has recommended a Rs 2 final dividend per equity share and proposed a 1:1 bonus share issue, pending shareholder approval.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
Historically, the company has paid a Rs 2 dividend each year since 2019, with the most recent ex-date for the upcoming dividend set for July 11, 2024. In addition to financial updates, the company announced its entry into Biologics Contract R&D services, focusing on novel biologic entities, biosimilars, and peptide-based therapeutics using microbial and mammalian platforms. These services will cover clone and process development, drug product development, and biosimilarity assessments.
Managing Director Harita Vasireddi expressed satisfaction with the company’s strong earnings, driven by growth in pharmaceutical services, particularly clinical and analytical segments. She highlighted capacity expansion, client engagement, and long-term investments as key drivers. The move into biologics R&D is seen as a strategic expansion aligned with future healthcare trends and is expected to strengthen the company’s position in biopharma innovation.
Founded in 1984 and based in Hyderabad, Vimta Labs offers scientific, technical, and regulatory support across industries including food, agriculture, pharmaceuticals, medical devices, speciality chemicals, and electronics, while also providing environmental testing services. The information provided is solely for informational purposes and does not constitute investment advice.
Investors should keep an eye on this Small-Cap stock
Disclaimer: The article is for informational purposes only and not investment advice.